These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 35904579)

  • 1. Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
    Pedrazzi JFC; Ferreira FR; Silva-Amaral D; Lima DA; Hallak JEC; Zuardi AW; Del-Bel EA; Guimarães FS; Costa KCM; Campos AC; Crippa ACS; Crippa JAS
    Psychopharmacology (Berl); 2022 Sep; 239(9):2713-2734. PubMed ID: 35904579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabidiol as a suggested candidate for treatment of autism spectrum disorder.
    Poleg S; Golubchik P; Offen D; Weizman A
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():90-96. PubMed ID: 30171992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of CBD in Autism Spectrum Disorder.
    Pedrazzi JFC; Hassib L; Ferreira FR; Hallak JC; Del-Bel E; Crippa JA
    Int Rev Neurobiol; 2024; 177():149-203. PubMed ID: 39029984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoid treatment for the symptoms of autism spectrum disorder.
    Aran A; Cayam Rand D
    Expert Opin Emerg Drugs; 2024 Mar; 29(1):65-79. PubMed ID: 38226593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of the endocannabinoid system and the therapeutic action of cannabinoids in autism spectrum disorder: A literature review.
    de Camargo RW; de Novais Júnior LR; da Silva LM; Meneguzzo V; Daros GC; da Silva MG; de Bitencourt RM
    Pharmacol Biochem Behav; 2022 Nov; 221():173492. PubMed ID: 36379443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of cannabidiol trials in neurodevelopmental disorders.
    Parrella NF; Hill AT; Enticott PG; Barhoun P; Bower IS; Ford TC
    Pharmacol Biochem Behav; 2023 Sep; 230():173607. PubMed ID: 37543051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models.
    Zamberletti E; Gabaglio M; Parolaro D
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28880200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of cannabinoids in neurodevelopmental disorders of children and adolescents.
    Dias-de Freitas F; Pimenta S; Soares S; Gonzaga D; Vaz-Matos I; Prior C
    Rev Neurol; 2022 Oct; 75(7):189-197. PubMed ID: 36169325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study.
    Lamberti M; Siracusano R; Italiano D; Alosi N; Cucinotta F; Di Rosa G; Germanò E; Spina E; Gagliano A
    Paediatr Drugs; 2016 Aug; 18(4):319-29. PubMed ID: 27278054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD).
    Pretzsch CM; Voinescu B; Mendez MA; Wichers R; Ajram L; Ivin G; Heasman M; Williams S; Murphy DG; Daly E; McAlonan GM
    J Psychopharmacol; 2019 Sep; 33(9):1141-1148. PubMed ID: 31237191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications.
    Holdman R; Vigil D; Robinson K; Shah P; Contreras AE
    Cannabis Cannabinoid Res; 2022 Aug; 7(4):451-463. PubMed ID: 34432543
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacological inhibition of the primary endocannabinoid producing enzyme, DGL-α, induces autism spectrum disorder-like and co-morbid phenotypes in adult C57BL/J mice.
    Fyke W; Alarcon JM; Velinov M; Chadman KK
    Autism Res; 2021 Jul; 14(7):1375-1389. PubMed ID: 33886158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retracing our steps: A review on autism research in children, its limitation and impending pharmacological interventions.
    Salloum-Asfar S; Zawia N; Abdulla SA
    Pharmacol Ther; 2024 Jan; 253():108564. PubMed ID: 38008401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autism Spectrum Disorder: A Review.
    Hirota T; King BH
    JAMA; 2023 Jan; 329(2):157-168. PubMed ID: 36625807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychopharmacological interventions in autism spectrum disorder.
    Accordino RE; Kidd C; Politte LC; Henry CA; McDougle CJ
    Expert Opin Pharmacother; 2016; 17(7):937-52. PubMed ID: 26891879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological management of behavioral disturbances in children and adolescents with autism spectrum disorders.
    Lamy M; Erickson CA
    Curr Probl Pediatr Adolesc Health Care; 2018 Oct; 48(10):250-264. PubMed ID: 30262163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study.
    Aran A; Cassuto H; Lubotzky A; Wattad N; Hazan E
    J Autism Dev Disord; 2019 Mar; 49(3):1284-1288. PubMed ID: 30382443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin Receptors as Therapeutic Targets for Autism Spectrum Disorder Treatment.
    Lee A; Choo H; Jeon B
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
    Anagnostou E
    Curr Opin Neurol; 2018 Apr; 31(2):119-125. PubMed ID: 29389748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autism Spectrum Disorder: Classification, diagnosis and therapy.
    Sharma SR; Gonda X; Tarazi FI
    Pharmacol Ther; 2018 Oct; 190():91-104. PubMed ID: 29763648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.